291 related articles for article (PubMed ID: 35100894)
1. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.
van Wifferen F; de Jonge L; Worthington J; Greuter MJE; Lew JB; Nadeau C; van den Puttelaar R; Feletto E; Yong JHE; Lansdorp-Vogelaar I; Canfell K; Coupé VMH;
J Med Screen; 2022 Jun; 29(2):72-83. PubMed ID: 35100894
[TBL] [Abstract][Full Text] [Related]
2. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.
de Jonge L; Worthington J; van Wifferen F; Iragorri N; Peterse EFP; Lew JB; Greuter MJE; Smith HA; Feletto E; Yong JHE; Canfell K; Coupé VMH; Lansdorp-Vogelaar I;
Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):304-314. PubMed ID: 33548185
[TBL] [Abstract][Full Text] [Related]
3. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
4. Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study.
Loveday C; Sud A; Jones ME; Broggio J; Scott S; Gronthound F; Torr B; Garrett A; Nicol DL; Jhanji S; Boyce SA; Williams M; Barry C; Riboli E; Kipps E; McFerran E; Muller DC; Lyratzopoulos G; Lawler M; Abulafi M; Houlston RS; Turnbull C
Gut; 2021 Jun; 70(6):1053-1060. PubMed ID: 32855306
[TBL] [Abstract][Full Text] [Related]
5. Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic.
de Jonge L; van de Schootbrugge-Vandermeer HJ; Breekveldt ECH; Spaander MCW; van Vuuren HJ; van Kemenade FJ; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
PLoS One; 2022; 17(6):e0270223. PubMed ID: 35749423
[TBL] [Abstract][Full Text] [Related]
6. Modelling the impact of the coronavirus pandemic on bowel cancer screening outcomes in England: A decision analysis to prepare for future screening disruption.
Mandrik O; Chilcott J; Thomas C
Prev Med; 2022 Jul; 160():107076. PubMed ID: 35526674
[TBL] [Abstract][Full Text] [Related]
7. Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening.
Worthington J; van Wifferen F; Sun Z; de Jonge L; Lew JB; Greuter MJE; van den Puttelaar R; Feletto E; Lansdorp-Vogelaar I; Coupé VMH; Ein Yong JH; Canfell K;
EClinicalMedicine; 2023 Aug; 62():102081. PubMed ID: 37538541
[TBL] [Abstract][Full Text] [Related]
8. Impact and Recovery from COVID-19-Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis.
van den Puttelaar R; Lansdorp-Vogelaar I; Hahn AI; Rutter CM; Levin TR; Zauber AG; Meester RGS
Cancer Epidemiol Biomarkers Prev; 2023 Jan; 32(1):22-29. PubMed ID: 36215205
[TBL] [Abstract][Full Text] [Related]
9. Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-based Population.
Lee JK; Lam AY; Jensen CD; Marks AR; Badalov J; Layefsky E; Kao K; Ho NJ; Schottinger JE; Ghai NR; Carlson CM; Halm EA; Green B; Li D; Corley DA; Levin TR
Gastroenterology; 2022 Sep; 163(3):723-731.e6. PubMed ID: 35580655
[TBL] [Abstract][Full Text] [Related]
10. A delay in the diagnosis of colorectal cancer screened by fecal immunochemical tests during the COVID-19 pandemic: a longitudinal cohort study.
Ishibashi F; Shida D; Suzuki S; Nagai M; Mochida K; Morishita T
Int J Colorectal Dis; 2022 Dec; 37(12):2543-2546. PubMed ID: 36383225
[TBL] [Abstract][Full Text] [Related]
11. Faecal immunochemical test outside colorectal cancer screening?
Pin-Vieito N; Puga M; Fernández-de-Castro D; Cubiella J
World J Gastroenterol; 2021 Oct; 27(38):6415-6429. PubMed ID: 34720531
[TBL] [Abstract][Full Text] [Related]
12. Lower Abnormal Fecal Immunochemical Test Cut-Off Values Improve Detection of Colorectal Cancer in System-Level Screens.
Berry E; Miller S; Koch M; Balasubramanian B; Argenbright K; Gupta S
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):647-653. PubMed ID: 31085338
[TBL] [Abstract][Full Text] [Related]
13. [Évaluation de la gravité du cancer colorectal dépisté dans le contexte de la crise sanitaire liée au COVID19 en région Ile-de-France].
Koïvogui A; Abihsera G; Le Trong T; Ait-Hadad H; Bernoux A; Delattre H; Vincelet C; Caroll R; Nicolet J
Rev Epidemiol Sante Publique; 2023 Oct; 71(5):102124. PubMed ID: 37451076
[TBL] [Abstract][Full Text] [Related]
14. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.
Knudsen AB; Zauber AG; Rutter CM; Naber SK; Doria-Rose VP; Pabiniak C; Johanson C; Fischer SE; Lansdorp-Vogelaar I; Kuntz KM
JAMA; 2016 Jun; 315(23):2595-609. PubMed ID: 27305518
[TBL] [Abstract][Full Text] [Related]
15. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
[TBL] [Abstract][Full Text] [Related]
16. Optimising colorectal cancer screening in Shanghai, China: a modelling study.
Cenin D; Li P; Wang J; de Jonge L; Yan B; Tao S; Lansdorp-Vogelaar I
BMJ Open; 2022 May; 12(5):e048156. PubMed ID: 35577474
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
18. The impact on clinical outcomes and healthcare resources from discontinuing colonoscopy surveillance subsequent to low-risk adenoma removal: A simulation study using the OncoSim-Colorectal model.
Steer KJ; Sun Z; Sadowski DC; Yong JHE; Coldman A; Nemecek N; Yang H
J Med Screen; 2024 Jun; 31(2):78-84. PubMed ID: 37728194
[TBL] [Abstract][Full Text] [Related]
19. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
Tinmouth J; Lansdorp-Vogelaar I; Allison JE
Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
[TBL] [Abstract][Full Text] [Related]
20. Short-term impact of the COVID-19 pandemic on a population-based screening program for colorectal cancer in Catalonia (Spain).
Vives N; Binefa G; Vidal C; Milà N; Muñoz R; Guardiola V; Rial O; Garcia M
Prev Med; 2022 Feb; 155():106929. PubMed ID: 34954239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
